NKLA Nikola | $9.33
-0.5% | 5/16/2024 | Initiated by | Bryan, Garnier & Co | - | Buy | $30.00 | Low | View details for Bryan, Garnier & Co rating of Nikola (NASDAQ:NKLA) on 5/16/2024 |
MLTX MoonLake Immunotherapeutics | $44.77
-0.3% | 9/14/2023 | Downgraded by | Bryan, Garnier & Co | - | Buy -> Neutral | | Low | View details for Bryan, Garnier & Co rating of MoonLake Immunotherapeutics (NASDAQ:MLTX) on 9/14/2023 |
TVTX Travere Therapeutics | $9.89
+1.2% | 5/5/2023 | Upgraded by | Bryan, Garnier & Co | - | Sell -> Neutral | | Low | View details for Bryan, Garnier & Co rating of Travere Therapeutics (NASDAQ:TVTX) on 5/5/2023 |
IMCR Immunocore | $40.13
0.0% | 3/24/2023 | Initiated by | Bryan, Garnier & Co | - | Buy | $16.00 | Low | View details for Bryan, Garnier & Co rating of Immunocore (NASDAQ:IMCR) on 3/24/2023 |
IMTX Immatics | $12.30
-0.7% | 3/24/2023 | Initiated by | Bryan, Garnier & Co | - | Buy | $16.00 | Low | View details for Bryan, Garnier & Co rating of Immatics (NASDAQ:IMTX) on 3/24/2023 |
ADAP Adaptimmune Therapeutics | $1.39
+6.9% | 3/24/2023 | Initiated by | Bryan, Garnier & Co | - | Buy | $3.60 | Low | View details for Bryan, Garnier & Co rating of Adaptimmune Therapeutics (NASDAQ:ADAP) on 3/24/2023 |
|
CRSP CRISPR Therapeutics | $57.92
+0.6% | 3/17/2023 | Initiated by | Bryan, Garnier & Co | - | Buy | $70.00 | Low | View details for Bryan, Garnier & Co rating of CRISPR Therapeutics (NASDAQ:CRSP) on 3/17/2023 |
CLLS Cellectis | $2.30
+12.2% | 3/17/2023 | Initiated by | Bryan, Garnier & Co | - | Buy | $6.00 | Low | View details for Bryan, Garnier & Co rating of Cellectis (NASDAQ:CLLS) on 3/17/2023 |
AUTL Autolus Therapeutics | $4.67
+1.5% | 3/17/2023 | Initiated by | Bryan, Garnier & Co | - | Buy | $5.00 | Low | View details for Bryan, Garnier & Co rating of Autolus Therapeutics (NASDAQ:AUTL) on 3/17/2023 |
MLTX MoonLake Immunotherapeutics | $44.77
-0.3% | 2/2/2023 | Initiated by | Bryan, Garnier & Co | - | Buy | $22.00 | Low | View details for Bryan, Garnier & Co rating of MoonLake Immunotherapeutics (NASDAQ:MLTX) on 2/2/2023 |
SAP SAP | €195.78
+0.3% | 12/14/2022 | Target Set by | Bryan, Garnier & Co | Analyst Gregory Ramirez | | €130.00 | N/A | View details for Bryan, Garnier & Co rating of SAP (ETR:SAP) on 12/14/2022 |
CRRFY Carrefour | $3.07
+1.3% | 11/16/2022 | Downgraded by | Bryan, Garnier & Co | Analyst Clement Genelot | Buy -> Neutral | $22.00 -> $20.00 | Low | View details for Bryan, Garnier & Co rating of Carrefour (OTCMKTS:CRRFY) on 11/16/2022 |
TVTX Travere Therapeutics | $9.89
+1.2% | 9/21/2022 | Initiated by | Bryan, Garnier & Co | - | Sell | $17.00 | Low | View details for Bryan, Garnier & Co rating of Travere Therapeutics (NASDAQ:TVTX) on 9/21/2022 |
SGBAF SES | $4.85
| 9/20/2022 | Initiated by | Bryan, Garnier & Co | Analyst Thomas Coudry | Neutral | $6.50 | Low | View details for Bryan, Garnier & Co rating of SES (OTCMKTS:SGBAF) on 9/20/2022 |
TAP Molson Coors Beverage | $54.33
+0.6% | 9/1/2022 | Downgraded by | Bryan, Garnier & Co | Analyst Nikolaas Faes | Buy -> Sell | $54.00 | Low | View details for Bryan, Garnier & Co rating of Molson Coors Beverage (NYSE:TAP) on 9/1/2022 |
ADRNY Koninklijke Ahold Delhaize | €32.49
+1.7% | 8/31/2022 | Upgraded by | Bryan, Garnier & Co | Analyst Clement Genelot | Neutral -> Buy | €31.00 -> €34.00 | Low | View details for Bryan, Garnier & Co rating of Koninklijke Ahold Delhaize (OTCMKTS:ADRNY) on 8/31/2022 |
ADYEY Adyen | $11.77
+3.9% | 8/19/2022 | Downgraded by | Bryan, Garnier & Co | - | Buy -> Neutral | | Low | View details for Bryan, Garnier & Co rating of Adyen (OTCMKTS:ADYEY) on 8/19/2022 |
CMPGY Compass Group | $30.74
+2.1% | 6/9/2022 | Upgraded by | Bryan, Garnier & Co | - | Neutral -> Buy | | Medium | View details for Bryan, Garnier & Co rating of Compass Group (OTCMKTS:CMPGY) on 6/9/2022 |
ZLNDY Zalando | $13.03
+2.0% | 6/1/2022 | Downgraded by | Bryan, Garnier & Co | Analyst Clement Genelot | Neutral -> Sell | $87.00 -> $38.00 | High | View details for Bryan, Garnier & Co rating of Zalando (OTCMKTS:ZLNDY) on 6/1/2022 |
GMAB Genmab A/S | $28.38
+0.9% | 5/13/2022 | Upgraded by | Bryan, Garnier & Co | Analyst Victor Floch | Sell -> Neutral | | Medium | View details for Bryan, Garnier & Co rating of Genmab A/S (NASDAQ:GMAB) on 5/13/2022 |
NVO Novo Nordisk A/S | $126.72
-0.9% | 5/5/2022 | Upgraded by | Bryan, Garnier & Co | - | Sell -> Neutral | | Low | View details for Bryan, Garnier & Co rating of Novo Nordisk A/S (NYSE:NVO) on 5/5/2022 |
BLDR Builders FirstSource | $167.64
+5.6% | 4/6/2022 | Downgraded by | Bryan, Garnier & Co | - | Buy -> Neutral | $71.00 | High | View details for Bryan, Garnier & Co rating of Builders FirstSource (NYSE:BLDR) on 4/6/2022 |
HNNMY H & M Hennes & Mauritz AB (publ) | $3.01
+0.3% | 4/4/2022 | Downgraded by | Bryan, Garnier & Co | Analyst Cedric Rossi | Buy -> Neutral | $225.00 -> $190.00 | Low | View details for Bryan, Garnier & Co rating of H & M Hennes & Mauritz AB (publ) (OTCMKTS:HNNMY) on 4/4/2022 |
MTLS Materialise | $5.70
-3.1% | 3/25/2022 | Downgraded by | Bryan, Garnier & Co | Analyst Gregory Ramirez | Buy -> Neutral | $20.00 | Low | View details for Bryan, Garnier & Co rating of Materialise (NASDAQ:MTLS) on 3/25/2022 |
DASTY Dassault Systèmes | $38.13
+4.5% | 3/25/2022 | Downgraded by | Bryan, Garnier & Co | Analyst Gregory Ramirez | Buy -> Neutral | $49.00 | High | View details for Bryan, Garnier & Co rating of Dassault Systèmes (OTCMKTS:DASTY) on 3/25/2022 |
ZLNDY Zalando | $13.03
+2.0% | 3/4/2022 | Downgraded by | Bryan, Garnier & Co | - | Neutral | | High | View details for Bryan, Garnier & Co rating of Zalando (OTCMKTS:ZLNDY) on 3/4/2022 |
GLPG Galapagos | $27.48
+0.3% | 1/28/2022 | Upgraded by | Bryan, Garnier & Co | - | Sell -> Buy | | High | View details for Bryan, Garnier & Co rating of Galapagos (NASDAQ:GLPG) on 1/28/2022 |
NVS Novartis | $110.30
+0.3% | 12/3/2021 | Reiterated by | Bryan, Garnier & Co | Analyst Jeanjacques Le | Buy -> Neutral | $115.00 -> $85.00 | Low | View details for Bryan, Garnier & Co rating of Novartis (NYSE:NVS) on 12/3/2021 |
AZN AstraZeneca | $78.13
-0.5% | 11/22/2021 | Downgraded by | Bryan, Garnier & Co | - | Buy | | Low | View details for Bryan, Garnier & Co rating of AstraZeneca (NASDAQ:AZN) on 11/22/2021 |
NVO Novo Nordisk A/S | $126.72
-0.9% | 11/3/2021 | Downgraded by | Bryan, Garnier & Co | Analyst Jean-Jacques Le | Buy -> Sell | $148.00 | High | View details for Bryan, Garnier & Co rating of Novo Nordisk A/S (NYSE:NVO) on 11/3/2021 |
ESLOY EssilorLuxottica Société anonyme | $111.50
+3.6% | 10/29/2021 | Upgraded by | Bryan, Garnier & Co | Analyst Cedric Rossi | Neutral -> Buy | | High | View details for Bryan, Garnier & Co rating of EssilorLuxottica Société anonyme (OTCMKTS:ESLOY) on 10/29/2021 |
MTTRY Ceconomy | $0.52
+4.0% | 10/12/2021 | Downgraded by | Bryan, Garnier & Co | Analyst Clement Genelot | Buy -> Neutral | | Low | View details for Bryan, Garnier & Co rating of Ceconomy (OTCMKTS:MTTRY) on 10/12/2021 |
BNTX BioNTech | $85.94
+1.5% | 10/5/2021 | Target Set by | Bryan, Garnier & Co | Analyst Olga Smolentseva | | $359.00 | Low | View details for Bryan, Garnier & Co rating of BioNTech (NASDAQ:BNTX) on 10/5/2021 |
BNTX BioNTech | $85.94
+1.5% | 9/24/2021 | Target Set by | Bryan, Garnier & Co | Analyst Olga Smolentseva | | $451.00 | High | View details for Bryan, Garnier & Co rating of BioNTech (NASDAQ:BNTX) on 9/24/2021 |
VALN Valneva | $7.25
| 9/13/2021 | Downgraded by | Bryan, Garnier & Co | Analyst Jean-Jacques Le Fur | Buy -> Neutral | | High | View details for Bryan, Garnier & Co rating of Valneva (NASDAQ:VALN) on 9/13/2021 |
ERFSF Eurofins Scientific | $59.63
+9.9% | 8/25/2021 | Downgraded by | Bryan, Garnier & Co | Analyst Bruno De | Strong-Buy -> Neutral | | Low | View details for Bryan, Garnier & Co rating of Eurofins Scientific (OTCMKTS:ERFSF) on 8/25/2021 |
BNTX BioNTech | $85.94
+1.5% | 8/11/2021 | Upgraded by | Bryan, Garnier & Co | Analyst Olga Smolentseva | Neutral -> Buy | | High | View details for Bryan, Garnier & Co rating of BioNTech (NASDAQ:BNTX) on 8/11/2021 |
AEXAY Atos | $0.18
| 7/13/2021 | Downgraded by | Bryan, Garnier & Co | Analyst Gregory Ramirez | Buy -> Sell | | Medium | View details for Bryan, Garnier & Co rating of Atos (OTCMKTS:AEXAY) on 7/13/2021 |
ERFSF Eurofins Scientific | $59.63
+9.9% | 7/9/2021 | Downgraded by | Bryan, Garnier & Co | Analyst Bruno De | Buy -> Neutral | | High | View details for Bryan, Garnier & Co rating of Eurofins Scientific (OTCMKTS:ERFSF) on 7/9/2021 |
MOR MorphoSys | $18.41
+0.2% | 6/3/2021 | Downgraded by | Bryan, Garnier & Co | - | Buy -> Neutral | | Medium | View details for Bryan, Garnier & Co rating of MorphoSys (NASDAQ:MOR) on 6/3/2021 |
Get out of cash before the Fed's next meeting (Ad) "How I 6X-ed my wife's 401K in 1 year"
At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains." Click here now to watch this exclusive interview |
BNTX BioNTech | $85.94
+1.5% | 5/17/2021 | Reiterated by | Bryan, Garnier & Co | - | Buy -> Neutral | $135.00 -> $206.00 | N/A | View details for Bryan, Garnier & Co rating of BioNTech (NASDAQ:BNTX) on 5/17/2021 |
BNTX BioNTech | $85.94
+1.5% | 5/11/2021 | Downgraded by | Bryan, Garnier & Co | - | Buy -> Neutral | $135.00 -> $206.00 | Low | View details for Bryan, Garnier & Co rating of BioNTech (NASDAQ:BNTX) on 5/11/2021 |
BUD Anheuser-Busch InBev SA/NV | $61.38
+1.1% | 5/6/2021 | Upgraded by | Bryan, Garnier & Co | - | Sell -> Buy | | Medium | View details for Bryan, Garnier & Co rating of Anheuser-Busch InBev SA/NV (NYSE:BUD) on 5/6/2021 |
DBVT DBV Technologies | $0.96
-6.8% | 5/3/2021 | Upgraded by | Bryan, Garnier & Co | - | Sell -> Buy | | Low | View details for Bryan, Garnier & Co rating of DBV Technologies (NASDAQ:DBVT) on 5/3/2021 |
AEXAY Atos | $0.18
| 4/6/2021 | Downgraded by | Bryan, Garnier & Co | - | Buy | | Low | View details for Bryan, Garnier & Co rating of Atos (OTCMKTS:AEXAY) on 4/6/2021 |
MTLS Materialise | $5.70
-3.1% | 3/10/2021 | Upgraded by | Bryan, Garnier & Co | - | Neutral -> Buy | $43.00 | High | View details for Bryan, Garnier & Co rating of Materialise (NASDAQ:MTLS) on 3/10/2021 |
ECIFY Electricité de France | $2.55
| 2/24/2021 | Downgraded by | Bryan, Garnier & Co | - | Neutral -> Sell | | Low | View details for Bryan, Garnier & Co rating of Electricité de France (OTCMKTS:ECIFY) on 2/24/2021 |
GNFT Genfit | $4.22
-6.6% | 2/12/2021 | Upgraded by | Bryan, Garnier & Co | - | Neutral -> Buy | | Low | View details for Bryan, Garnier & Co rating of Genfit (NASDAQ:GNFT) on 2/12/2021 |
IPHYF Innate Pharma | $1.93
| 2/9/2021 | Upgraded by | Bryan, Garnier & Co | - | Neutral -> Buy | | Low | View details for Bryan, Garnier & Co rating of Innate Pharma (OTCMKTS:IPHYF) on 2/9/2021 |
DASTY Dassault Systèmes | $38.13
+4.5% | 2/5/2021 | Upgraded by | Bryan, Garnier & Co | - | Sell -> Buy | | Low | View details for Bryan, Garnier & Co rating of Dassault Systèmes (OTCMKTS:DASTY) on 2/5/2021 |
VCISY Vinci | $29.33
+3.5% | 1/14/2021 | Upgraded by | Bryan, Garnier & Co | - | Sell -> Neutral | | Medium | View details for Bryan, Garnier & Co rating of Vinci (OTCMKTS:VCISY) on 1/14/2021 |
STM STMicroelectronics | $33.99
+1.6% | 1/8/2021 | Upgraded by | Bryan, Garnier & Co | - | Neutral -> Buy | | High | View details for Bryan, Garnier & Co rating of STMicroelectronics (NYSE:STM) on 1/8/2021 |
GLPG Galapagos | $27.48
+0.3% | 12/17/2020 | Downgraded by | Bryan, Garnier & Co | - | Buy -> Sell | | High | View details for Bryan, Garnier & Co rating of Galapagos (NASDAQ:GLPG) on 12/17/2020 |
SCRYY Scor | $2.33
+2.2% | 12/17/2020 | Downgraded by | Bryan, Garnier & Co | - | Buy | | Low | View details for Bryan, Garnier & Co rating of Scor (OTCMKTS:SCRYY) on 12/17/2020 |
ITMPF ITM Power | $0.69
-4.2% | 12/11/2020 | Initiated by | Bryan, Garnier & Co | - | Buy | | Low | View details for Bryan, Garnier & Co rating of ITM Power (OTCMKTS:ITMPF) on 12/11/2020 |
STM STMicroelectronics | $33.99
+1.6% | 12/10/2020 | Downgraded by | Bryan, Garnier & Co | - | Buy -> Neutral | | Low | View details for Bryan, Garnier & Co rating of STMicroelectronics (NYSE:STM) on 12/10/2020 |
GMAB Genmab A/S | $28.38
+0.9% | 9/23/2020 | Downgraded by | Bryan, Garnier & Co | - | Neutral -> Sell | | High | View details for Bryan, Garnier & Co rating of Genmab A/S (NASDAQ:GMAB) on 9/23/2020 |
IHG InterContinental Hotels Group | $103.54
+0.8% | 9/21/2020 | Downgraded by | Bryan, Garnier & Co | - | Neutral -> Sell | | Low | View details for Bryan, Garnier & Co rating of InterContinental Hotels Group (NYSE:IHG) on 9/21/2020 |
IPHA Innate Pharma | $2.13
+1.9% | 9/9/2020 | Downgraded by | Bryan, Garnier & Co | - | Buy -> Neutral | | Low | View details for Bryan, Garnier & Co rating of Innate Pharma (NASDAQ:IPHA) on 9/9/2020 |
DBVT DBV Technologies | $0.96
-6.8% | 8/4/2020 | Downgraded by | Bryan, Garnier & Co | - | Neutral -> Sell | | High | View details for Bryan, Garnier & Co rating of DBV Technologies (NASDAQ:DBVT) on 8/4/2020 |
BUD Anheuser-Busch InBev SA/NV | $61.38
+1.1% | 7/15/2020 | Downgraded by | Bryan, Garnier & Co | - | Buy -> Sell | | Low | View details for Bryan, Garnier & Co rating of Anheuser-Busch InBev SA/NV (NYSE:BUD) on 7/15/2020 |
TAP Molson Coors Beverage | $54.33
+0.6% | 7/15/2020 | Upgraded by | Bryan, Garnier & Co | - | Sell -> Buy | $49.00 | Low | View details for Bryan, Garnier & Co rating of Molson Coors Beverage (NYSE:TAP) on 7/15/2020 |
DEO Diageo | $132.44
+1.3% | 7/8/2020 | Upgraded by | Bryan, Garnier & Co | - | Neutral -> Buy | | Low | View details for Bryan, Garnier & Co rating of Diageo (NYSE:DEO) on 7/8/2020 |
BNTX BioNTech | $85.94
+1.5% | 7/2/2020 | Target Raised by | Bryan, Garnier & Co | - | | $50.00 -> $62.00 | High | View details for Bryan, Garnier & Co rating of BioNTech (NASDAQ:BNTX) on 7/2/2020 |
STM STMicroelectronics | $33.99
+1.6% | 6/29/2020 | Upgraded by | Bryan, Garnier & Co | - | Neutral -> Buy | | Low | View details for Bryan, Garnier & Co rating of STMicroelectronics (NYSE:STM) on 6/29/2020 |
GMAB Genmab A/S | $28.38
+0.9% | 6/3/2020 | Downgraded by | Bryan, Garnier & Co | - | Buy -> Neutral | | Low | View details for Bryan, Garnier & Co rating of Genmab A/S (NASDAQ:GMAB) on 6/3/2020 |
AZN AstraZeneca | £121.80
+1.0% | 6/2/2020 | Target Raised by | Bryan, Garnier & Co | - | Buy | GBX 8,780 -> GBX 9,100 | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 6/2/2020 |
CGC Canopy Growth | $7.30
+2.0% | 6/1/2020 | Downgraded by | Bryan, Garnier & Co | - | Neutral -> Sell | | High | View details for Bryan, Garnier & Co rating of Canopy Growth (NASDAQ:CGC) on 6/1/2020 |
GNFT Genfit | $4.22
-6.6% | 5/13/2020 | Downgraded by | Bryan, Garnier & Co | - | Buy -> Neutral | | Medium | View details for Bryan, Garnier & Co rating of Genfit (NASDAQ:GNFT) on 5/13/2020 |
AZN AstraZeneca | £121.80
+1.0% | 5/11/2020 | Target Raised by | Bryan, Garnier & Co | - | Buy | GBX 8,550 -> GBX 8,780 | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 5/11/2020 |
ORAN Orange | $11.17
+0.4% | 3/27/2020 | Upgraded by | Bryan, Garnier & Co | - | Neutral -> Buy | | Low | View details for Bryan, Garnier & Co rating of Orange (NYSE:ORAN) on 3/27/2020 |
DBVT DBV Technologies | $0.96
-6.8% | 3/18/2020 | Downgraded by | Bryan, Garnier & Co | - | Buy -> Neutral | | High | View details for Bryan, Garnier & Co rating of DBV Technologies (NASDAQ:DBVT) on 3/18/2020 |
SGE The Sage Group | GBX 1,082
+2.1% | 3/2/2020 | Target Lowered by | Bryan, Garnier & Co | - | Neutral | GBX 690 -> GBX 680 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 3/2/2020 |
BUD Anheuser-Busch InBev SA/NV | $61.38
+1.1% | 2/28/2020 | Downgraded by | Bryan, Garnier & Co | - | Buy -> Neutral | | High | View details for Bryan, Garnier & Co rating of Anheuser-Busch InBev SA/NV (NYSE:BUD) on 2/28/2020 |
ACB Aurora Cannabis | $5.90
+1.9% | 2/27/2020 | Downgraded by | Bryan, Garnier & Co | - | Neutral -> Sell | | Low | View details for Bryan, Garnier & Co rating of Aurora Cannabis (NASDAQ:ACB) on 2/27/2020 |
GSK GSK | GBX 1,553
+1.9% | 2/6/2020 | Target Lowered by | Bryan, Garnier & Co | - | Neutral | GBX 1,800 -> GBX 1,773 | N/A | View details for Bryan, Garnier & Co rating of GSK (LON:GSK) on 2/6/2020 |
SAP SAP | €195.78
+0.3% | 1/28/2020 | Target Set by | Bryan, Garnier & Co | - | Buy | €153.00 | N/A | View details for Bryan, Garnier & Co rating of SAP (ETR:SAP) on 1/28/2020 |
ASML ASML | $888.39
+3.0% | 1/14/2020 | Upgraded by | Bryan, Garnier & Co | - | Neutral -> Buy | | Medium | View details for Bryan, Garnier & Co rating of ASML (NASDAQ:ASML) on 1/14/2020 |
BRBY Burberry Group | GBX 747.20
+4.2% | 1/10/2020 | Target Raised by | Bryan, Garnier & Co | - | Neutral | GBX 1,780 -> GBX 1,860 | N/A | View details for Bryan, Garnier & Co rating of Burberry Group (LON:BRBY) on 1/10/2020 |
AZN AstraZeneca | £121.80
+1.0% | 12/19/2019 | Reiterated by | Bryan, Garnier & Co | - | Buy | | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 12/19/2019 |
GSK GSK | GBX 1,553
+1.9% | 12/19/2019 | Target Raised by | Bryan, Garnier & Co | - | Neutral | GBX 1,660 -> GBX 1,747 | N/A | View details for Bryan, Garnier & Co rating of GSK (LON:GSK) on 12/19/2019 |
ORAN Orange | $11.17
+0.4% | 12/5/2019 | Downgraded by | Bryan, Garnier & Co | - | Buy -> Neutral | | Low | View details for Bryan, Garnier & Co rating of Orange (NYSE:ORAN) on 12/5/2019 |
AZN AstraZeneca | £121.80
+1.0% | 11/25/2019 | Upgraded by | Bryan, Garnier & Co | - | Buy | GBX 7,700 -> GBX 7,950 | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 11/25/2019 |
CABGY Carlsberg A/S | $25.03
+1.8% | 8/12/2019 | Upgraded by | Bryan, Garnier & Co | - | Neutral -> Buy | | Low | View details for Bryan, Garnier & Co rating of Carlsberg A/S (OTCMKTS:CABGY) on 8/12/2019 |
TAP Molson Coors Beverage | $54.33
+0.6% | 8/1/2019 | Reiterated by | Bryan, Garnier & Co | - | Neutral -> Sell | $51.00 | High | View details for Bryan, Garnier & Co rating of Molson Coors Beverage (NYSE:TAP) on 8/1/2019 |
CGC Canopy Growth | $7.30
+2.0% | 7/5/2019 | Downgraded by | Bryan, Garnier & Co | - | Buy -> Neutral | | Low | View details for Bryan, Garnier & Co rating of Canopy Growth (NASDAQ:CGC) on 7/5/2019 |
WEED Canopy Growth | C$10.07
+1.6% | 7/4/2019 | Downgraded by | Bryan, Garnier & Co | - | Buy -> Neutral | C$85.00 -> C$60.00 | N/A | View details for Bryan, Garnier & Co rating of Canopy Growth (TSE:WEED) on 7/4/2019 |
AZN AstraZeneca | £121.80
+1.0% | 7/3/2019 | Reiterated by | Bryan, Garnier & Co | - | Neutral | | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 7/3/2019 |
SCH SafeCharge International Group | GBX 451
+90,100.0% | 5/24/2019 | Reiterated by | Bryan, Garnier & Co | - | Buy | | N/A | View details for Bryan, Garnier & Co rating of SafeCharge International Group (LON:SCH) on 5/24/2019 |
BURBY Burberry Group | $9.74
+3.0% | 5/20/2019 | Upgraded by | Bryan, Garnier & Co | - | Sell -> Neutral | | Low | View details for Bryan, Garnier & Co rating of Burberry Group (OTCMKTS:BURBY) on 5/20/2019 |
Get out of cash before the Fed's next meeting (Ad) "How I 6X-ed my wife's 401K in 1 year"
At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains." Click here now to watch this exclusive interview |
BRBY Burberry Group | GBX 747.20
+4.2% | 5/20/2019 | Upgraded by | Bryan, Garnier & Co | - | Neutral | | N/A | View details for Bryan, Garnier & Co rating of Burberry Group (LON:BRBY) on 5/20/2019 |
GSK GSK | GBX 1,553
+1.9% | 5/2/2019 | Target Lowered by | Bryan, Garnier & Co | - | Neutral | GBX 1,710 -> GBX 1,660 | N/A | View details for Bryan, Garnier & Co rating of GSK (LON:GSK) on 5/2/2019 |
PDRDY Pernod Ricard | $47.12
| 3/29/2019 | Downgraded by | Bryan, Garnier & Co | - | Buy -> Neutral | | Low | View details for Bryan, Garnier & Co rating of Pernod Ricard (OTCMKTS:PDRDY) on 3/29/2019 |
AZN AstraZeneca | £121.80
+1.0% | 3/29/2019 | Reiterated by | Bryan, Garnier & Co | - | Neutral | | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 3/29/2019 |
AZN AstraZeneca | £121.80
+1.0% | 2/22/2019 | Downgraded by | Bryan, Garnier & Co | - | Neutral | | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 2/22/2019 |
IHG InterContinental Hotels Group | GBX 7,988
-0.1% | 2/19/2019 | Reiterated by | Bryan, Garnier & Co | - | Sell | | N/A | View details for Bryan, Garnier & Co rating of InterContinental Hotels Group (LON:IHG) on 2/19/2019 |
SGE The Sage Group | GBX 1,082
+2.1% | 1/17/2019 | Target Lowered by | Bryan, Garnier & Co | - | Buy | GBX 850 -> GBX 630 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 1/17/2019 |
AZN AstraZeneca | £121.80
+1.0% | 11/8/2018 | Downgraded by | Bryan, Garnier & Co | - | Neutral | | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 11/8/2018 |
SCH SafeCharge International Group | GBX 451
+90,100.0% | 9/13/2018 | Target Raised by | Bryan, Garnier & Co | - | Buy | GBX 354 -> GBX 380 | N/A | View details for Bryan, Garnier & Co rating of SafeCharge International Group (LON:SCH) on 9/13/2018 |
LVMUY LVMH Moët Hennessy - Louis Vuitton, Société Européenne | $144.28
+1.0% | 4/24/2018 | Upgraded by | Bryan, Garnier & Co | - | Neutral -> Buy | | Medium | View details for Bryan, Garnier & Co rating of LVMH Moët Hennessy - Louis Vuitton, Société Européenne (OTCMKTS:LVMUY) on 4/24/2018 |
SOW Software Aktiengesellschaft | €36.68
| 4/17/2018 | Target Set by | Bryan, Garnier & Co | - | Buy | €49.00 | N/A | View details for Bryan, Garnier & Co rating of Software Aktiengesellschaft (ETR:SOW) on 4/17/2018 |
MOR MorphoSys | €67.85
+0.1% | 4/9/2018 | Target Set by | Bryan, Garnier & Co | - | Buy | €91.00 | N/A | View details for Bryan, Garnier & Co rating of MorphoSys (ETR:MOR) on 4/9/2018 |
SAP SAP | €195.78
+0.3% | 4/6/2018 | Target Set by | Bryan, Garnier & Co | - | Buy | €112.00 | N/A | View details for Bryan, Garnier & Co rating of SAP (ETR:SAP) on 4/6/2018 |
MOR MorphoSys | €67.85
+0.1% | 3/14/2018 | Target Set by | Bryan, Garnier & Co | - | Buy | €91.20 | N/A | View details for Bryan, Garnier & Co rating of MorphoSys (ETR:MOR) on 3/14/2018 |
IGY innogy SE (IGY.F) | €43.60
| 3/12/2018 | Target Set by | Bryan, Garnier & Co | - | Neutral | €31.00 | N/A | View details for Bryan, Garnier & Co rating of innogy SE (IGY.F) (ETR:IGY) on 3/12/2018 |
IHG InterContinental Hotels Group | GBX 7,988
-0.1% | 2/20/2018 | Reiterated by | Bryan, Garnier & Co | - | Sell | GBX 4,100 | N/A | View details for Bryan, Garnier & Co rating of InterContinental Hotels Group (LON:IHG) on 2/20/2018 |
DGE Diageo | GBX 2,565.50
+1.3% | 1/25/2018 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 2,320 | N/A | View details for Bryan, Garnier & Co rating of Diageo (LON:DGE) on 1/25/2018 |
SGE The Sage Group | GBX 1,082
+2.1% | 1/25/2018 | Target Lowered by | Bryan, Garnier & Co | - | Buy | GBX 860 -> GBX 850 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 1/25/2018 |
AZN AstraZeneca | £121.80
+1.0% | 12/15/2017 | Reiterated by | Bryan, Garnier & Co | - | Buy | | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 12/15/2017 |
SGE The Sage Group | GBX 1,082
+2.1% | 11/23/2017 | Target Raised by | Bryan, Garnier & Co | - | Buy | GBX 830 -> GBX 860 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 11/23/2017 |
BRBY Burberry Group | GBX 747.20
+4.2% | 11/10/2017 | Reiterated by | Bryan, Garnier & Co | - | Sell | | N/A | View details for Bryan, Garnier & Co rating of Burberry Group (LON:BRBY) on 11/10/2017 |
ULVR Unilever | GBX 4,741
+1.5% | 10/20/2017 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 4,350 | N/A | View details for Bryan, Garnier & Co rating of Unilever (LON:ULVR) on 10/20/2017 |
SGPYY The Sage Group | $55.99
+1.3% | 9/24/2017 | Upgraded by | Bryan, Garnier & Co | - | Neutral -> Buy | | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (OTCMKTS:SGPYY) on 9/24/2017 |
SGPYY The Sage Group | $55.99
+1.3% | 9/22/2017 | Upgraded by | Bryan, Garnier & Co | - | Neutral -> Buy | | Low | View details for Bryan, Garnier & Co rating of The Sage Group (OTCMKTS:SGPYY) on 9/22/2017 |
SGE The Sage Group | GBX 1,082
+2.1% | 9/22/2017 | Upgraded by | Bryan, Garnier & Co | - | Buy | GBX 720 -> GBX 830 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 9/22/2017 |
GSK GSK | GBX 1,553
+1.9% | 9/19/2017 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 1,710 | N/A | View details for Bryan, Garnier & Co rating of GSK (LON:GSK) on 9/19/2017 |
TSCO Tesco | GBX 327.10
+0.5% | 9/12/2017 | Reiterated by | Bryan, Garnier & Co | - | Sell | GBX 170 | N/A | View details for Bryan, Garnier & Co rating of Tesco (LON:TSCO) on 9/12/2017 |
AZN AstraZeneca | £121.80
+1.0% | 9/11/2017 | Upgraded by | Bryan, Garnier & Co | - | Buy | GBX 4,700 -> GBX 5,380 | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 9/11/2017 |
BRBY Burberry Group | GBX 747.20
+4.2% | 9/11/2017 | Reiterated by | Bryan, Garnier & Co | - | Sell | | N/A | View details for Bryan, Garnier & Co rating of Burberry Group (LON:BRBY) on 9/11/2017 |
CPG Compass Group | GBX 2,361
+2.4% | 8/29/2017 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 1,550 | N/A | View details for Bryan, Garnier & Co rating of Compass Group (LON:CPG) on 8/29/2017 |
ULVR Unilever | GBX 4,741
+1.5% | 8/25/2017 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 4,300 | N/A | View details for Bryan, Garnier & Co rating of Unilever (LON:ULVR) on 8/25/2017 |
IHG InterContinental Hotels Group | GBX 7,988
-0.1% | 8/24/2017 | Reiterated by | Bryan, Garnier & Co | - | Sell | GBX 3,520 | N/A | View details for Bryan, Garnier & Co rating of InterContinental Hotels Group (LON:IHG) on 8/24/2017 |
DGE Diageo | GBX 2,565.50
+1.3% | 8/23/2017 | Target Raised by | Bryan, Garnier & Co | - | Neutral | GBX 2,210 -> GBX 2,320 | N/A | View details for Bryan, Garnier & Co rating of Diageo (LON:DGE) on 8/23/2017 |
GSK GSK | GBX 1,553
+1.9% | 7/26/2017 | Target Raised by | Bryan, Garnier & Co | - | Buy | GBX 1,750 -> GBX 1,790 | N/A | View details for Bryan, Garnier & Co rating of GSK (LON:GSK) on 7/26/2017 |
GSK GSK | GBX 1,553
+1.9% | 7/20/2017 | Reiterated by | Bryan, Garnier & Co | - | Buy | GBX 1,750 | N/A | View details for Bryan, Garnier & Co rating of GSK (LON:GSK) on 7/20/2017 |
TSCO Tesco | GBX 327.10
+0.5% | 6/20/2017 | Reiterated by | Bryan, Garnier & Co | - | Sell | GBX 170 | N/A | View details for Bryan, Garnier & Co rating of Tesco (LON:TSCO) on 6/20/2017 |
TSCO Tesco | GBX 327.10
+0.5% | 6/14/2017 | Reiterated by | Bryan, Garnier & Co | - | Sell | GBX 170 | N/A | View details for Bryan, Garnier & Co rating of Tesco (LON:TSCO) on 6/14/2017 |
GSK GSK | GBX 1,553
+1.9% | 5/31/2017 | Reiterated by | Bryan, Garnier & Co | - | Buy | GBX 1,750 | N/A | View details for Bryan, Garnier & Co rating of GSK (LON:GSK) on 5/31/2017 |
BRBY Burberry Group | GBX 747.20
+4.2% | 4/20/2017 | Reiterated by | Bryan, Garnier & Co | - | Sell | | N/A | View details for Bryan, Garnier & Co rating of Burberry Group (LON:BRBY) on 4/20/2017 |
BRBY Burberry Group | GBX 747.20
+4.2% | 4/13/2017 | Reiterated by | Bryan, Garnier & Co | - | Sell | GBX 1,350 | N/A | View details for Bryan, Garnier & Co rating of Burberry Group (LON:BRBY) on 4/13/2017 |
TSCO Tesco | GBX 327.10
+0.5% | 4/13/2017 | Reiterated by | Bryan, Garnier & Co | - | Sell | GBX 170 | N/A | View details for Bryan, Garnier & Co rating of Tesco (LON:TSCO) on 4/13/2017 |
TSCO Tesco | GBX 327.10
+0.5% | 3/23/2017 | Reiterated by | Bryan, Garnier & Co | - | Sell | GBX 170 | N/A | View details for Bryan, Garnier & Co rating of Tesco (LON:TSCO) on 3/23/2017 |
DGE Diageo | GBX 2,565.50
+1.3% | 3/17/2017 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 2,210 | N/A | View details for Bryan, Garnier & Co rating of Diageo (LON:DGE) on 3/17/2017 |
SGE The Sage Group | GBX 1,082
+2.1% | 3/6/2017 | Target Raised by | Bryan, Garnier & Co | - | Neutral | GBX 640 -> GBX 660 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 3/6/2017 |
AZN AstraZeneca | £121.80
+1.0% | 2/28/2017 | Reiterated by | Bryan, Garnier & Co | - | Buy | GBX 5,400 | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 2/28/2017 |
IHG InterContinental Hotels Group | GBX 7,988
-0.1% | 2/21/2017 | Reiterated by | Bryan, Garnier & Co | - | Sell | GBX 2,950 | N/A | View details for Bryan, Garnier & Co rating of InterContinental Hotels Group (LON:IHG) on 2/21/2017 |
CPG Compass Group | GBX 2,361
+2.4% | 2/3/2017 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 1,475 | N/A | View details for Bryan, Garnier & Co rating of Compass Group (LON:CPG) on 2/3/2017 |
SGE The Sage Group | GBX 1,082
+2.1% | 2/1/2017 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 640 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 2/1/2017 |
TSCO Tesco | GBX 327.10
+0.5% | 1/30/2017 | Reiterated by | Bryan, Garnier & Co | - | Sell | GBX 170 | N/A | View details for Bryan, Garnier & Co rating of Tesco (LON:TSCO) on 1/30/2017 |
ULVR Unilever | GBX 4,741
+1.5% | 1/27/2017 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 3,570 | N/A | View details for Bryan, Garnier & Co rating of Unilever (LON:ULVR) on 1/27/2017 |
Get out of cash before the Fed's next meeting (Ad) "How I 6X-ed my wife's 401K in 1 year"
At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains." Click here now to watch this exclusive interview |
DGE Diageo | GBX 2,565.50
+1.3% | 1/26/2017 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 2,150 | N/A | View details for Bryan, Garnier & Co rating of Diageo (LON:DGE) on 1/26/2017 |
SGE The Sage Group | GBX 1,082
+2.1% | 1/26/2017 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 650 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 1/26/2017 |
BRBY Burberry Group | GBX 747.20
+4.2% | 1/18/2017 | Reiterated by | Bryan, Garnier & Co | - | Sell | GBX 1,350 | N/A | View details for Bryan, Garnier & Co rating of Burberry Group (LON:BRBY) on 1/18/2017 |
DGE Diageo | GBX 2,565.50
+1.3% | 1/16/2017 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 2,150 | N/A | View details for Bryan, Garnier & Co rating of Diageo (LON:DGE) on 1/16/2017 |
MRK Merck & Co., Inc. | $125.30
-0.4% | 1/13/2017 | Initiated by | Bryan, Garnier & Co | - | Buy | | N/A | View details for Bryan, Garnier & Co rating of Merck & Co., Inc. (NYSE:MRK) on 1/13/2017 |
BRBY Burberry Group | GBX 747.20
+4.2% | 1/10/2017 | Reiterated by | Bryan, Garnier & Co | - | Sell | GBX 1,350 | N/A | View details for Bryan, Garnier & Co rating of Burberry Group (LON:BRBY) on 1/10/2017 |
CPG Compass Group | GBX 2,361
+2.4% | 1/9/2017 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 1,430 | N/A | View details for Bryan, Garnier & Co rating of Compass Group (LON:CPG) on 1/9/2017 |
AZN AstraZeneca | £121.80
+1.0% | 1/9/2017 | Reiterated by | Bryan, Garnier & Co | - | Buy | GBX 5,250 | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 1/9/2017 |
GSK GSK | GBX 1,553
+1.9% | 1/9/2017 | Reiterated by | Bryan, Garnier & Co | - | Buy | GBX 1,850 | N/A | View details for Bryan, Garnier & Co rating of GSK (LON:GSK) on 1/9/2017 |
PNN Pennon Group | GBX 620.50
+1.1% | 1/6/2017 | Reiterated by | Bryan, Garnier & Co | - | Sell | GBX 830 | N/A | View details for Bryan, Garnier & Co rating of Pennon Group (LON:PNN) on 1/6/2017 |
BRBY Burberry Group | GBX 747.20
+4.2% | 1/4/2017 | Downgraded by | Bryan, Garnier & Co | - | Sell | GBX 1,350 | N/A | View details for Bryan, Garnier & Co rating of Burberry Group (LON:BRBY) on 1/4/2017 |
DGE Diageo | GBX 2,565.50
+1.3% | 1/4/2017 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 2,150 | N/A | View details for Bryan, Garnier & Co rating of Diageo (LON:DGE) on 1/4/2017 |
ULVR Unilever | GBX 4,741
+1.5% | 1/4/2017 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 3,990 | N/A | View details for Bryan, Garnier & Co rating of Unilever (LON:ULVR) on 1/4/2017 |
TSCO Tesco | GBX 327.10
+0.5% | 1/4/2017 | Reiterated by | Bryan, Garnier & Co | - | Sell | GBX 170 | N/A | View details for Bryan, Garnier & Co rating of Tesco (LON:TSCO) on 1/4/2017 |
AZN AstraZeneca | £121.80
+1.0% | 12/12/2016 | Reiterated by | Bryan, Garnier & Co | - | Buy | GBX 5,100 | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 12/12/2016 |
SGE The Sage Group | GBX 1,082
+2.1% | 11/30/2016 | Reiterated by | Bryan, Garnier & Co | - | Sell | GBX 690 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 11/30/2016 |
CMPGY Compass Group | $30.74
+2.1% | 11/25/2016 | Reiterated by | Bryan, Garnier & Co | - | Neutral | | N/A | View details for Bryan, Garnier & Co rating of Compass Group (OTCMKTS:CMPGY) on 11/25/2016 |
DGE Diageo | GBX 2,565.50
+1.3% | 11/23/2016 | Reiterated by | Bryan, Garnier & Co | - | Neutral | | N/A | View details for Bryan, Garnier & Co rating of Diageo (LON:DGE) on 11/23/2016 |
AZN AstraZeneca | £121.80
+1.0% | 11/22/2016 | Reiterated by | Bryan, Garnier & Co | - | Buy | GBX 5,100 | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 11/22/2016 |
CPG Compass Group | GBX 2,361
+2.4% | 11/22/2016 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 1,450 | N/A | View details for Bryan, Garnier & Co rating of Compass Group (LON:CPG) on 11/22/2016 |
AZN AstraZeneca | £121.80
+1.0% | 10/26/2016 | Reiterated by | Bryan, Garnier & Co | - | Buy | GBX 5,220 | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 10/26/2016 |
BRBY Burberry Group | GBX 747.20
+4.2% | 10/25/2016 | Target Raised by | Bryan, Garnier & Co | - | Neutral | GBX 1,260 -> GBX 1,350 | N/A | View details for Bryan, Garnier & Co rating of Burberry Group (LON:BRBY) on 10/25/2016 |
BRBY Burberry Group | GBX 747.20
+4.2% | 10/19/2016 | Target Raised by | Bryan, Garnier & Co | - | Neutral | GBX 1,200 -> GBX 1,250 | N/A | View details for Bryan, Garnier & Co rating of Burberry Group (LON:BRBY) on 10/19/2016 |
AZN AstraZeneca | £121.80
+1.0% | 10/17/2016 | Reiterated by | Bryan, Garnier & Co | - | Buy | GBX 5,220 | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 10/17/2016 |
GSK GSK | GBX 1,553
+1.9% | 10/17/2016 | Reiterated by | Bryan, Garnier & Co | - | Buy | | N/A | View details for Bryan, Garnier & Co rating of GSK (LON:GSK) on 10/17/2016 |
SGE The Sage Group | GBX 1,082
+2.1% | 10/12/2016 | Target Raised by | Bryan, Garnier & Co | - | Sell | GBX 600 -> GBX 690 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 10/12/2016 |
TSCO Tesco | GBX 327.10
+0.5% | 10/5/2016 | Reiterated by | Bryan, Garnier & Co | - | Sell | GBX 166 | N/A | View details for Bryan, Garnier & Co rating of Tesco (LON:TSCO) on 10/5/2016 |
AZN AstraZeneca | £121.80
+1.0% | 10/4/2016 | Target Lowered by | Bryan, Garnier & Co | - | Buy | GBX 5,400 -> GBX 5,220 | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 10/4/2016 |
SGE The Sage Group | GBX 1,082
+2.1% | 9/30/2016 | Reiterated by | Bryan, Garnier & Co | - | Sell | GBX 600 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 9/30/2016 |
IHG InterContinental Hotels Group | GBX 7,988
-0.1% | 9/27/2016 | Downgraded by | Bryan, Garnier & Co | - | Sell | GBX 2,650 -> GBX 2,950 | N/A | View details for Bryan, Garnier & Co rating of InterContinental Hotels Group (LON:IHG) on 9/27/2016 |
AZN AstraZeneca | £121.80
+1.0% | 7/28/2016 | Reiterated by | Bryan, Garnier & Co | - | Buy | | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 7/28/2016 |
GSK GSK | GBX 1,553
+1.9% | 7/28/2016 | Reiterated by | Bryan, Garnier & Co | - | Buy | | N/A | View details for Bryan, Garnier & Co rating of GSK (LON:GSK) on 7/28/2016 |
TAP Molson Coors Beverage | $54.33
+0.6% | 7/8/2016 | Upgraded by | Bryan, Garnier & Co | - | Buy | | N/A | View details for Bryan, Garnier & Co rating of Molson Coors Beverage (NYSE:TAP) on 7/8/2016 |
SGE The Sage Group | GBX 1,082
+2.1% | 5/5/2016 | Reiterated by | Bryan, Garnier & Co | - | Sell | GBX 550 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 5/5/2016 |
TSCO Tesco | GBX 327.10
+0.5% | 4/4/2016 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 166 | N/A | View details for Bryan, Garnier & Co rating of Tesco (LON:TSCO) on 4/4/2016 |
CPG Compass Group | GBX 2,361
+2.4% | 4/4/2016 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 1,200 | N/A | View details for Bryan, Garnier & Co rating of Compass Group (LON:CPG) on 4/4/2016 |
AZN AstraZeneca | £121.80
+1.0% | 3/10/2016 | Reiterated by | Bryan, Garnier & Co | - | Buy | GBX 5,520 | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 3/10/2016 |
PNN Pennon Group | GBX 620.50
+1.1% | 2/11/2016 | Downgraded by | Bryan, Garnier & Co | - | Sell | GBX 825 | N/A | View details for Bryan, Garnier & Co rating of Pennon Group (LON:PNN) on 2/11/2016 |
PNN Pennon Group | GBX 620.50
+1.1% | 2/4/2016 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 800 | N/A | View details for Bryan, Garnier & Co rating of Pennon Group (LON:PNN) on 2/4/2016 |
SGE The Sage Group | GBX 1,082
+2.1% | 1/28/2016 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 570 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 1/28/2016 |
GSK GSK | $39.86
+2.0% | 1/27/2016 | Upgraded by | Bryan, Garnier & Co | - | Neutral -> Buy | | N/A | View details for Bryan, Garnier & Co rating of GSK (NYSE:GSK) on 1/27/2016 |
GSK GSK | GBX 1,553
+1.9% | 1/27/2016 | Upgraded by | Bryan, Garnier & Co | - | Buy | GBX 1,635 | N/A | View details for Bryan, Garnier & Co rating of GSK (LON:GSK) on 1/27/2016 |
ASML ASML | $888.39
+3.0% | 1/21/2016 | Upgraded by | Bryan, Garnier & Co | - | Neutral -> Buy | | N/A | View details for Bryan, Garnier & Co rating of ASML (NASDAQ:ASML) on 1/21/2016 |
TSCO Tesco | GBX 327.10
+0.5% | 1/14/2016 | Initiated by | Bryan, Garnier & Co | - | Neutral | GBX 166 | N/A | View details for Bryan, Garnier & Co rating of Tesco (LON:TSCO) on 1/14/2016 |
PNN Pennon Group | GBX 620.50
+1.1% | 1/8/2016 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 800 | N/A | View details for Bryan, Garnier & Co rating of Pennon Group (LON:PNN) on 1/8/2016 |
IHG InterContinental Hotels Group | GBX 7,988
-0.1% | 1/7/2016 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 2,650 | N/A | View details for Bryan, Garnier & Co rating of InterContinental Hotels Group (LON:IHG) on 1/7/2016 |
CPG Compass Group | GBX 2,361
+2.4% | 1/5/2016 | Target Raised by | Bryan, Garnier & Co | - | Neutral | GBX 1,150 -> GBX 1,200 | N/A | View details for Bryan, Garnier & Co rating of Compass Group (LON:CPG) on 1/5/2016 |
SGE The Sage Group | GBX 1,082
+2.1% | 12/18/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 540 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 12/18/2015 |
GLPG Galapagos | $27.48
+0.3% | 12/17/2015 | Target Raised by | Bryan, Garnier & Co | - | Buy | $52.00 -> $64.00 | N/A | View details for Bryan, Garnier & Co rating of Galapagos (NASDAQ:GLPG) on 12/17/2015 |
DGE Diageo | GBX 2,565.50
+1.3% | 12/3/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 1,870 | N/A | View details for Bryan, Garnier & Co rating of Diageo (LON:DGE) on 12/3/2015 |
Man Who Called Nvidia at $1.10 Says Buy This Now... (Ad) In 2004, one man called Nvidia before just about anyone knew it existed.
Now, this same guy says a new company could become the next to soar like Nvidia. Watch Alex's "Next Magnificent Seven" presentation now. |
TSCO Tesco | GBX 327.10
+0.5% | 12/1/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | | N/A | View details for Bryan, Garnier & Co rating of Tesco (LON:TSCO) on 12/1/2015 |
PNN Pennon Group | GBX 620.50
+1.1% | 11/27/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 800 | N/A | View details for Bryan, Garnier & Co rating of Pennon Group (LON:PNN) on 11/27/2015 |
SGE The Sage Group | GBX 1,082
+2.1% | 11/27/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 540 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 11/27/2015 |
TSCDY Tesco | $12.82
+1.0% | 11/25/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | | N/A | View details for Bryan, Garnier & Co rating of Tesco (OTCMKTS:TSCDY) on 11/25/2015 |
TSCO Tesco | GBX 327.10
+0.5% | 11/25/2015 | Initiated by | Bryan, Garnier & Co | - | Neutral | | N/A | View details for Bryan, Garnier & Co rating of Tesco (LON:TSCO) on 11/25/2015 |
CPG Compass Group | GBX 2,361
+2.4% | 11/24/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 1,150 | N/A | View details for Bryan, Garnier & Co rating of Compass Group (LON:CPG) on 11/24/2015 |
TAP Molson Coors Beverage | $54.33
+0.6% | 11/17/2015 | Initiated by | Bryan, Garnier & Co | - | Buy | $101.00 | N/A | View details for Bryan, Garnier & Co rating of Molson Coors Beverage (NYSE:TAP) on 11/17/2015 |
SGE The Sage Group | GBX 1,082
+2.1% | 11/13/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 540 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 11/13/2015 |
AZN AstraZeneca | £121.80
+1.0% | 11/12/2015 | Target Raised by | Bryan, Garnier & Co | - | Buy | GBX 5,100 -> GBX 5,150 | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 11/12/2015 |
SNY Sanofi | $52.40
-1.3% | 11/9/2015 | Reiterated by | Bryan, Garnier & Co | - | Buy -> Neutral | | N/A | View details for Bryan, Garnier & Co rating of Sanofi (NASDAQ:SNY) on 11/9/2015 |
PNN Pennon Group | GBX 620.50
+1.1% | 10/26/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 800 | N/A | View details for Bryan, Garnier & Co rating of Pennon Group (LON:PNN) on 10/26/2015 |
AZN AstraZeneca | £121.80
+1.0% | 10/23/2015 | Reiterated by | Bryan, Garnier & Co | - | Buy | GBX 5,100 | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 10/23/2015 |
UBSFY Ubisoft Entertainment | $4.04
+2.3% | 10/15/2015 | Upgraded by | Bryan, Garnier & Co | - | Neutral -> Buy | | N/A | View details for Bryan, Garnier & Co rating of Ubisoft Entertainment (OTCMKTS:UBSFY) on 10/15/2015 |
AZN AstraZeneca | £121.80
+1.0% | 10/12/2015 | Reiterated by | Bryan, Garnier & Co | - | Buy | GBX 5,400 | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 10/12/2015 |
SGE The Sage Group | GBX 1,082
+2.1% | 10/6/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 520 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 10/6/2015 |
IHG InterContinental Hotels Group | GBX 7,988
-0.1% | 10/5/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | | N/A | View details for Bryan, Garnier & Co rating of InterContinental Hotels Group (LON:IHG) on 10/5/2015 |
DGE Diageo | GBX 2,565.50
+1.3% | 10/1/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 1,870 | N/A | View details for Bryan, Garnier & Co rating of Diageo (LON:DGE) on 10/1/2015 |
DGE Diageo | GBX 2,565.50
+1.3% | 9/23/2015 | Target Lowered by | Bryan, Garnier & Co | - | Neutral | GBX 1,920 -> GBX 1,870 | N/A | View details for Bryan, Garnier & Co rating of Diageo (LON:DGE) on 9/23/2015 |
AZN AstraZeneca | $78.13
-0.5% | 9/18/2015 | Upgraded by | Bryan, Garnier & Co | - | Neutral -> Buy | | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (NASDAQ:AZN) on 9/18/2015 |
AZN AstraZeneca | £121.80
+1.0% | 9/10/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 4,830 | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 9/10/2015 |
GSK GSK | GBX 1,553
+1.9% | 9/9/2015 | Target Lowered by | Bryan, Garnier & Co | - | Neutral | GBX 1,480 -> GBX 1,470 | N/A | View details for Bryan, Garnier & Co rating of GSK (LON:GSK) on 9/9/2015 |
PNN Pennon Group | GBX 620.50
+1.1% | 8/25/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 835 | N/A | View details for Bryan, Garnier & Co rating of Pennon Group (LON:PNN) on 8/25/2015 |
GSK GSK | GBX 1,553
+1.9% | 8/21/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 1,480 | N/A | View details for Bryan, Garnier & Co rating of GSK (LON:GSK) on 8/21/2015 |
AZN AstraZeneca | £121.80
+1.0% | 8/21/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 4,830 | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 8/21/2015 |
DGE Diageo | GBX 2,565.50
+1.3% | 7/29/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 1,920 | N/A | View details for Bryan, Garnier & Co rating of Diageo (LON:DGE) on 7/29/2015 |
SGE The Sage Group | GBX 1,082
+2.1% | 7/21/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 520 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 7/21/2015 |
VCISY Vinci | $29.33
+3.5% | 7/17/2015 | Initiated by | Bryan, Garnier & Co | - | Buy | | N/A | View details for Bryan, Garnier & Co rating of Vinci (OTCMKTS:VCISY) on 7/17/2015 |
DANOY Danone | $12.83
+1.4% | 7/8/2015 | Initiated by | Bryan, Garnier & Co | - | Buy | | N/A | View details for Bryan, Garnier & Co rating of Danone (OTCMKTS:DANOY) on 7/8/2015 |
DGE Diageo | GBX 2,565.50
+1.3% | 7/2/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 1,920 | N/A | View details for Bryan, Garnier & Co rating of Diageo (LON:DGE) on 7/2/2015 |
DASTY Dassault Systèmes | $38.13
+4.5% | 6/30/2015 | Downgraded by | Bryan, Garnier & Co | - | Neutral -> Sell | | N/A | View details for Bryan, Garnier & Co rating of Dassault Systèmes (OTCMKTS:DASTY) on 6/30/2015 |
NVS Novartis | $110.30
+0.3% | 6/22/2015 | Upgraded by | Bryan, Garnier & Co | - | Neutral -> Buy | | N/A | View details for Bryan, Garnier & Co rating of Novartis (NYSE:NVS) on 6/22/2015 |
DLGNF Dialog Semiconductor | $80.41
| 6/11/2015 | Initiated by | Bryan, Garnier & Co | - | Buy | | N/A | View details for Bryan, Garnier & Co rating of Dialog Semiconductor (OTCMKTS:DLGNF) on 6/11/2015 |
GSK GSK | GBX 1,553
+1.9% | 6/2/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 1,580 | N/A | View details for Bryan, Garnier & Co rating of GSK (LON:GSK) on 6/2/2015 |
IHG InterContinental Hotels Group | GBX 7,988
-0.1% | 5/21/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 2,650 | N/A | View details for Bryan, Garnier & Co rating of InterContinental Hotels Group (LON:IHG) on 5/21/2015 |
UBSFY Ubisoft Entertainment | $4.04
+2.3% | 5/13/2015 | Downgraded by | Bryan, Garnier & Co | - | Buy -> Neutral | | N/A | View details for Bryan, Garnier & Co rating of Ubisoft Entertainment (OTCMKTS:UBSFY) on 5/13/2015 |
DGE Diageo | GBX 2,565.50
+1.3% | 5/6/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 1,950 | N/A | View details for Bryan, Garnier & Co rating of Diageo (LON:DGE) on 5/6/2015 |
CABGY Carlsberg A/S | $25.03
+1.8% | 5/5/2015 | Initiated by | Bryan, Garnier & Co | - | Neutral | | N/A | View details for Bryan, Garnier & Co rating of Carlsberg A/S (OTCMKTS:CABGY) on 5/5/2015 |
BUD Anheuser-Busch InBev SA/NV | $61.38
+1.1% | 5/5/2015 | Initiated by | Bryan, Garnier & Co | - | Neutral | | N/A | View details for Bryan, Garnier & Co rating of Anheuser-Busch InBev SA/NV (NYSE:BUD) on 5/5/2015 |
AEG Aegon | $6.35
+1.4% | 4/15/2015 | Upgraded by | Bryan, Garnier & Co | - | Neutral -> Buy | | N/A | View details for Bryan, Garnier & Co rating of Aegon (NYSE:AEG) on 4/15/2015 |
RANJY Randstad | $24.51
+1.0% | 4/14/2015 | Upgraded by | Bryan, Garnier & Co | - | Sell -> Buy | | N/A | View details for Bryan, Garnier & Co rating of Randstad (OTCMKTS:RANJY) on 4/14/2015 |
AZN AstraZeneca | £121.80
+1.0% | 4/10/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 4,740 | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (LON:AZN) on 4/10/2015 |
DGE Diageo | GBX 2,565.50
+1.3% | 4/1/2015 | Target Raised by | Bryan, Garnier & Co | - | Neutral | GBX 1,880 -> GBX 2,000 | N/A | View details for Bryan, Garnier & Co rating of Diageo (LON:DGE) on 4/1/2015 |
CPG Compass Group | GBX 2,361
+2.4% | 3/30/2015 | Target Raised by | Bryan, Garnier & Co | - | Neutral | GBX 1,070 -> GBX 1,220 | N/A | View details for Bryan, Garnier & Co rating of Compass Group (LON:CPG) on 3/30/2015 |
NVO Novo Nordisk A/S | $126.72
-0.9% | 3/26/2015 | Downgraded by | Bryan, Garnier & Co | - | Neutral | | N/A | View details for Bryan, Garnier & Co rating of Novo Nordisk A/S (NYSE:NVO) on 3/26/2015 |
PPRUY Kering | $30.84
+1.9% | 2/18/2015 | Downgraded by | Bryan, Garnier & Co | - | Neutral | | N/A | View details for Bryan, Garnier & Co rating of Kering (OTCMKTS:PPRUY) on 2/18/2015 |
LVMUY LVMH Moët Hennessy - Louis Vuitton, Société Européenne | $144.28
+1.0% | 2/4/2015 | Upgraded by | Bryan, Garnier & Co | - | Buy | | N/A | View details for Bryan, Garnier & Co rating of LVMH Moët Hennessy - Louis Vuitton, Société Européenne (OTCMKTS:LVMUY) on 2/4/2015 |
SGE The Sage Group | GBX 1,082
+2.1% | 1/29/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 450 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 1/29/2015 |
SGE The Sage Group | GBX 1,082
+2.1% | 1/13/2015 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 420 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 1/13/2015 |
FMS Fresenius Medical Care | $20.30
-0.4% | 12/18/2014 | Downgraded by | Bryan, Garnier & Co | - | Neutral | | N/A | View details for Bryan, Garnier & Co rating of Fresenius Medical Care (NYSE:FMS) on 12/18/2014 |
DEO Diageo | $132.44
+1.3% | 12/4/2014 | Initiated by | Bryan, Garnier & Co | - | Neutral | | N/A | View details for Bryan, Garnier & Co rating of Diageo (NYSE:DEO) on 12/4/2014 |
SGE The Sage Group | GBX 1,082
+2.1% | 12/4/2014 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 425 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 12/4/2014 |
VEOEY Veolia Environnement | $15.71
+1.2% | 9/30/2014 | Initiated by | Bryan, Garnier & Co | - | Buy | | N/A | View details for Bryan, Garnier & Co rating of Veolia Environnement (OTCMKTS:VEOEY) on 9/30/2014 |
SGE The Sage Group | GBX 1,082
+2.1% | 9/30/2014 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 405 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 9/30/2014 |
CRH CRH | $81.56
+2.5% | 9/12/2014 | Upgraded by | Bryan, Garnier & Co | - | Sell -> Buy | | N/A | View details for Bryan, Garnier & Co rating of CRH (NYSE:CRH) on 9/12/2014 |
PDRDY Pernod Ricard | $47.12
| 8/29/2014 | Upgraded by | Bryan, Garnier & Co | - | Neutral -> Buy | $23.29 | N/A | View details for Bryan, Garnier & Co rating of Pernod Ricard (OTCMKTS:PDRDY) on 8/29/2014 |
SGE The Sage Group | GBX 1,082
+2.1% | 7/24/2014 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 395 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 7/24/2014 |
PDRDY Pernod Ricard | $47.12
| 5/28/2014 | Initiated by | Bryan, Garnier & Co | - | Neutral | | N/A | View details for Bryan, Garnier & Co rating of Pernod Ricard (OTCMKTS:PDRDY) on 5/28/2014 |
SGE The Sage Group | GBX 1,082
+2.1% | 4/17/2014 | Reiterated by | Bryan, Garnier & Co | - | Neutral | GBX 410 | N/A | View details for Bryan, Garnier & Co rating of The Sage Group (LON:SGE) on 4/17/2014 |
AZN AstraZeneca | $78.13
-0.5% | 12/20/2013 | Downgraded by | Bryan, Garnier & Co | - | Buy -> Neutral | | N/A | View details for Bryan, Garnier & Co rating of AstraZeneca (NASDAQ:AZN) on 12/20/2013 |
AXAHY AXA | $35.40
+1.2% | 6/12/2013 | Reiterated by | Bryan, Garnier & Co | - | Buy | $18.50 | N/A | View details for Bryan, Garnier & Co rating of AXA (OTCMKTS:AXAHY) on 6/12/2013 |
